At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 537 enrolled
Drug / intervention
Retatrutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
In Brief
A Phase 3 clinical trial evaluating Retatrutide and Placebo for Diabetes Type 2. Completed, enrolled 537 participants across 48 sites in 4 countries.
Detailed Summary
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Type 2
CountriesIndia, Mexico, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
First PostedApr 2024
Enrollment StartApr 2024
Primary CompletionJan 2026
Study CompletionFeb 2026
TodayJul 2026
First PostedApr 9, 2024
Enrollment StartApr 10, 2024
Primary CompletionJan 22, 2026
Study CompletionFeb 20, 2026
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 2.2 years ago
Interventions
Retatrutidedrug
Administered SC.
Placebodrug
Administered SC.